Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHA 2008: Blood test identifies heart failure patients in ER

This article was originally published in Clinica

Executive Summary

A new blood test identifies the sickest heart failure patients better than current tests used in US emergency departments, a trial has shown. Presented at the AHA meeting, the BACH study followed 1,641 patients who experienced difficulty breathing upon arrival at the emergency department. The researchers found that the MR-proADM test, developed by German firm Brahms, was prognostically accurate 73.1% of the time, making it superior to the commonly-used B-natriuretic peptide (BNP) test (60.6%) and the NTproBNP test (63%). The new test also predicted the 90-day mortality of these patients. The MR-proADM test indirectly measures adrenomedullin, which affects blood vessel dilation and is implicated in many cardiac and infectious diseases. It was CE marked for sale in Europe in October; US approval applications will be submitted in early 2009.

You may also be interested in...

Five minutes with… Noam Emanuel of PolyPid

Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.

Mesoblast's blood cancers stem cell therapy moves closer to market

Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.

Mesoblast stem cell therapy advances into Phase II for spinal degeneration

Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts